BioSpace News Archive

Biotech Beach

Viracta Therapeutics Reacquires Exclusive Development and Commercialization Rights for its All-Oral Combination Therapy in China

Viracta Therapeutics, Inc. today announced that it has reacquired the exclusive rights to develop and commercialize its all-oral combination product candidate in the People’s Republic of China previously licensed to Shenzhen Salubris Pharmaceuticals Co., Ltd.

August 23, 2021
·
5 min read
PharmAbcine to Participate in H.C. Wainright 23rd Annual Global Investment Conference

PharmAbcine Inc. announced today that the Company will participate in H.C. Wainright 23 rd Annual Global Investment Conference taking place virtually from September 13-15, 2021 .

August 23, 2021
·
3 min read
Biotech Bay

NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research

NGM Biopharmaceuticals, Inc. today disclosed its fourth oncology development candidate, NGM831, an antagonist antibody designed to block the interaction of ILT3 with fibronectin, as well as with other ligands.

August 23, 2021
·
9 min read
Policy

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD)

Bristol Myers Squibb announced that the U.S. Food and Drug Administration has accepted its supplemental Biologics License Application for Orencia for the prevention of moderate to severe acute graft versus host disease in patients 6 years of age and older receiving unrelated donor hematopoietic stem cell transplantation.

August 23, 2021
·
14 min read
Study Confirms Viraleze Antiviral Nasal Spray Provides Protection Against SARS-CoV-2 in Challenge Model

Melbourne biotech company Starpharma has announced the publication of new data demonstrating the capability of its Viraleze antiviral nasal spray to protect against SARS-CoV-2 in an animal challenge model of SARS-CoV-2 infection[1].

August 23, 2021
·
2 min read
BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021

BELLUS Health Inc. announced that an abstract covering additional data from the RELIEF Phase 2a trial has been accepted for oral presentation at the upcoming European Respiratory Society International Congress 2021, being held September 5-8, 2021.

August 23, 2021
·
7 min read
FDA

FDA Grants 510(k) Market Clearance to Vivos Therapeutics’ mmRNA Oral Appliance for Treating Mild to Moderate Sleep Apnea

Vivos Therapeutics, Inc today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance to Vivos’ mmRNA device for treating mild to moderate OSA, sleep-disordered breathing and snoring in adults.

August 23, 2021
·
5 min read
BioForest

Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer’s Disease Summit

Athira Pharma, Inc. today announced that Chief Medical Officer, Hans Moebius, will present on the application of clinically established Evoked-Response Potentials (ERPs) by using ERP P300 in Alzheimer’s drug development

August 23, 2021
·
1 min read
Business

NeuPath and Cynergi Collaborate to Advance Virtual Reality and Remote Pain Management Technology in Treatment of Chronic Pain

NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment announced today a Memorandum of Understanding (“MoU”) with Texas-based Cynergi Health Partners (“Cynergi”),

August 23, 2021
·
4 min read